Nifty
Sensex
:
:
10192.95
33053.04
-47.20 (-0.46%)
-174.95 (-0.53%)

Pharmaceuticals & Drugs

Rating :
42/99

BSE: 506690 | NSE: UNICHEMLAB

296.85
-3.55 (-1.18%)
13-Dec-2017 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 299.95
  • 301.75
  • 295.80
  • 300.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 44989
  • 133.55
  • 347.00
  • 231.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,737.17
  • 26.10
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,819.10
  • 1.00%
  • 2.39

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.77%
  • 0%
  • 18.76%
  • FII
  • DII
  • Others
  • 0.04%
  • 9.78%
  • 19.65%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Standalone Figures in Rs. Crores

Description
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Net Sales
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PBT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
1,519.50
1,332.65
1,201.79
1,133.45
1,080.80
875.46
824.04
747.39
735.23
671.35
Net Sales Growth
14.02%
10.89%
6.03%
4.87%
23.46%
6.24%
10.26%
1.65%
9.52%
 
Cost Of Goods Sold
442.72
386.97
378.57
332.84
343.06
278.55
237.98
225.17
244.13
256.57
Gross Profit
1,076.78
945.67
823.23
800.61
737.75
596.91
586.07
522.22
491.10
414.77
GP Margin
70.86%
70.96%
68.50%
70.63%
68.26%
68.18%
71.12%
69.87%
66.80%
61.78%
Total Expenditure
1,340.90
1,168.77
1,100.79
955.75
910.06
759.42
674.08
576.53
593.04
584.99
Power & Fuel Cost
46.13
38.25
39.39
35.97
31.36
26.22
22.50
16.23
15.00
14.64
% Of Sales
3.04%
2.87%
3.28%
3.17%
2.90%
2.99%
2.73%
2.17%
2.04%
2.18%
Employee Cost
300.09
255.92
223.20
187.37
164.88
140.06
123.99
99.31
95.96
91.38
% Of Sales
19.75%
19.20%
18.57%
16.53%
15.26%
16.00%
15.05%
13.29%
13.05%
13.61%
Manufacturing Exp.
174.59
150.54
145.03
137.05
119.15
101.54
102.67
77.15
78.86
89.25
% Of Sales
11.49%
11.30%
12.07%
12.09%
11.02%
11.60%
12.46%
10.32%
10.73%
13.29%
General & Admin Exp.
162.94
167.66
153.29
127.77
104.73
88.54
79.74
71.83
71.35
49.91
% Of Sales
10.72%
12.58%
12.76%
11.27%
9.69%
10.11%
9.68%
9.61%
9.70%
7.43%
Selling & Distn. Exp.
212.35
166.84
157.12
134.03
135.93
116.00
106.52
80.88
80.92
75.60
% Of Sales
13.97%
12.52%
13.07%
11.82%
12.58%
13.25%
12.93%
10.82%
11.01%
11.26%
Miscellaneous Exp.
2.06
2.58
4.19
0.73
10.97
8.50
0.70
5.96
6.83
75.60
% Of Sales
0.14%
0.19%
0.35%
0.06%
1.01%
0.97%
0.08%
0.80%
0.93%
1.14%
EBITDA
178.60
163.88
101.00
177.70
170.74
116.04
149.96
170.86
142.19
86.36
EBITDA Margin
11.75%
12.30%
8.40%
15.68%
15.80%
13.25%
18.20%
22.86%
19.34%
12.86%
Other Income
11.02
19.11
20.72
42.38
16.96
12.50
8.32
7.98
10.13
7.46
Interest
3.37
2.90
3.04
3.19
3.29
4.08
2.39
2.38
2.56
2.19
Depreciation
45.18
38.79
41.27
45.72
38.34
30.43
29.22
23.21
22.41
18.14
PBT
141.07
141.31
77.41
171.17
146.07
94.03
126.66
153.24
127.36
73.48
Tax
32.58
29.30
2.13
43.00
32.85
22.77
31.68
30.43
19.20
16.75
Tax Rate
23.09%
21.27%
2.75%
25.12%
22.49%
24.22%
25.01%
19.86%
15.08%
24.59%
PAT
108.49
108.48
75.28
128.16
113.23
71.26
94.98
122.81
108.16
51.39
PAT before Minority Interest
108.49
108.48
75.28
128.16
113.23
71.26
94.98
122.81
108.16
51.39
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
7.14%
8.14%
6.26%
11.31%
10.48%
8.14%
11.53%
16.43%
14.71%
7.65%
PAT Growth
0.01%
44.10%
-41.26%
13.19%
58.90%
-24.97%
-22.66%
13.54%
110.47%
 
Unadjusted EPS
11.92
11.86
8.31
18.69
12.52
7.89
10.53
34.14
29.97
14.26

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
1,063.62
954.33
867.52
816.61
727.07
660.58
617.70
562.92
484.45
411.52
Share Capital
18.18
18.17
18.15
18.13
18.09
18.06
18.05
18.03
18.03
18.02
Total Reserves
1,044.00
935.01
848.52
797.74
707.98
641.80
598.85
544.19
464.39
392.10
Non-Current Liabilities
64.49
76.02
74.21
97.72
94.31
92.67
87.44
70.46
72.10
56.59
Secured Loans
0.44
22.98
20.35
24.65
20.89
20.47
19.01
15.29
20.95
6.49
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
23.49
22.72
20.48
18.78
17.83
Long Term Provisions
25.33
12.58
8.88
7.64
9.19
10.24
7.90
0.00
0.00
0.00
Current Liabilities
455.81
275.09
211.76
230.32
251.12
233.30
176.15
165.34
146.30
134.84
Trade Payables
218.03
163.95
138.23
150.52
156.63
140.30
109.99
115.14
101.30
90.05
Other Current Liabilities
68.01
60.56
45.86
32.99
36.65
34.28
26.00
14.56
15.77
11.15
Short Term Borrowings
97.62
12.93
1.63
1.04
6.17
25.42
9.04
0.00
0.00
0.00
Short Term Provisions
72.15
37.65
26.05
45.78
51.67
33.30
31.13
35.64
29.23
33.64
Total Liabilities
1,583.92
1,305.44
1,153.49
1,144.65
1,072.50
986.55
881.29
798.72
702.85
602.95
Net Block
491.00
402.60
415.99
419.29
447.76
408.39
377.31
333.35
300.81
238.21
Gross Block
565.36
439.53
724.65
688.25
675.87
599.27
537.04
464.60
414.13
333.01
Accumulated Depreciation
74.35
36.92
308.66
268.96
228.11
190.87
159.73
131.25
113.31
94.80
Non Current Assets
760.03
673.34
589.07
563.97
594.06
547.20
456.50
396.26
376.76
341.48
Capital Work in Progress
249.98
237.13
122.64
90.54
132.20
112.76
62.87
62.88
75.93
103.19
Non Current Investment
5.72
5.54
5.83
5.72
5.72
0.03
0.03
0.03
0.02
0.08
Long Term Loans & Adv.
13.33
28.05
44.61
48.42
8.38
26.02
16.29
0.00
0.00
0.00
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
823.89
632.11
564.42
580.68
478.44
439.35
424.79
402.46
326.08
261.46
Current Investments
8.00
8.04
35.04
5.67
33.06
14.50
21.29
59.18
1.00
0.00
Inventories
281.71
230.57
207.68
203.49
143.05
157.96
150.26
107.54
103.39
83.28
Sundry Debtors
320.49
220.09
191.58
196.51
206.95
183.25
185.13
166.97
151.59
139.93
Cash & Bank
16.14
20.13
26.96
52.15
24.64
23.23
15.16
23.64
34.37
10.05
Other Current Assets
197.55
30.51
20.92
17.19
70.75
60.40
52.95
45.13
35.73
28.20
Short Term Loans & Adv.
170.98
122.77
82.25
105.67
61.73
53.14
47.14
45.13
35.73
28.20
Net Current Assets
368.08
357.02
352.66
350.36
227.32
206.05
248.65
237.12
179.78
126.62
Total Assets
1,583.92
1,305.45
1,153.49
1,144.65
1,072.50
986.55
881.29
798.72
702.84
602.94

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
111.91
78.10
86.73
171.23
124.08
68.59
129.10
102.77
70.03
46.79
PBT
137.68
77.41
171.17
146.07
94.03
126.66
153.24
127.36
68.13
88.09
Adjustment
39.65
35.57
18.74
47.15
39.37
27.54
25.31
25.49
24.23
12.79
Changes in Working Capital
-34.16
-16.49
-66.32
13.05
13.51
-54.81
-21.95
-29.70
-11.21
-42.22
Cash after chg. in Working capital
143.16
96.49
123.58
206.27
146.91
99.39
156.60
123.14
81.15
58.66
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-31.25
-18.39
-36.85
-35.04
-22.83
-30.81
-27.50
-20.37
-11.12
-11.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-85.33
-52.34
35.70
-118.45
-101.80
-47.60
-100.15
-57.94
-82.25
-60.72
Net Fixed Assets
154.89
-73.58
38.14
-92.98
-106.47
-67.03
-39.23
-45.49
-80.05
-81.78
Net Investments
42.09
-32.73
20.34
-34.14
-5.98
28.17
-67.50
-19.00
-5.19
-9.13
Others
-282.31
53.97
-22.78
8.67
10.65
-8.74
6.58
6.55
2.99
30.19
Cash from Financing Activity
-33.42
-50.95
-94.92
-51.38
-14.21
-29.46
-39.68
-20.52
-4.91
-45.31
Net Cash Inflow / Outflow
-6.84
-25.19
27.51
1.41
8.07
-8.48
-10.73
24.31
-17.13
-59.24
Opening Cash & Equivalents
26.96
52.15
24.64
23.23
15.16
23.64
34.37
10.05
27.19
86.43
Closing Cash & Equivalent
20.13
26.96
52.15
24.64
23.23
15.16
23.64
34.36
10.05
27.19

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
116.88
104.93
95.48
90.02
80.27
73.06
68.36
62.36
53.52
45.52
ROA
7.51%
8.82%
6.55%
11.56%
11.00%
7.63%
11.31%
16.36%
16.57%
8.84%
ROE
10.77%
11.92%
8.95%
16.62%
16.34%
11.16%
16.11%
23.51%
24.24%
13.01%
ROCE
13.42%
14.97%
9.29%
21.84%
20.13%
14.03%
20.37%
27.72%
27.06%
16.68%
Fixed Asset Turnover
3.06
2.32
1.71
1.67
1.71
1.55
1.66
1.71
1.99
2.20
Receivable days
64.25
55.72
58.55
64.53
65.42
76.34
77.46
77.49
71.68
75.09
Inventory Days
60.89
59.32
62.03
55.42
50.47
63.88
56.72
51.31
45.90
44.74
Payable days
56.76
52.00
52.61
62.52
65.77
65.64
63.82
75.73
62.75
61.87
Cash Conversion Cycle
68.38
63.05
67.97
57.43
50.11
74.58
70.36
53.06
54.83
57.97
Total Debt/Equity
0.09
0.04
0.03
0.03
0.04
0.11
0.08
0.06
0.08
0.06
Interest Cover
42.87
48.57
26.45
54.66
45.40
24.06
53.94
65.29
50.85
32.04

News Update:


  • Unichem to sell, transfer domestic formulations business in India and Nepal
    4th Nov 2017, 09:21 AM

    It will include the portfolio of several brands in India and Nepal, manufacturing facility at Sikkim and employees performing work in relation to the transferred business

    Read More
  • Unichem Lab - Quarterly Results
    3rd Nov 2017, 12:00 AM

    Read More
  • Unichem recalls 96,876 bottles of Bisoprolol Fumarate tablets from US market
    27th Oct 2017, 08:50 AM

    It has initiated a class II recall, a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences

    Read More
  • Unichem receives ANDA approval for Irbesartan, Hydrochlorothiazide Tablets
    20th Sep 2017, 14:24 PM

    The product will be commercialized from Unichem's Ghaziabad plant

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.